Treatment of the cholesterol biosynthetic defect in Smith-Lemli-Opitz syndrome reproduced in rats by BM 15.766
β Scribed by Guorong Xu; Gerald Salen; Sarah Shefer; Gene C. Ness; Thomas S. Chen; Zhihong Zhao; Louis Salen; G.Stephen Tint
- Book ID
- 118882000
- Publisher
- Elsevier Science
- Year
- 1995
- Tongue
- English
- Weight
- 750 KB
- Volume
- 109
- Category
- Article
- ISSN
- 0016-5085
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
A limitation to treating Smith-Lemli-Opitz infants by giving dietary cholesterol is their impaired ability to absorb cholesterol due to a deficiency of bile acids. Since intravenously administered lipoprotein cholesterol should not require bile acids for uptake into tissues, we tested the effects of
The Smith-Lemli-Opitz syndrome (SLOS) is a common condition caused by deficiency of 7-dehydrocholesterol β¬ 7 -reductase. The syndrome can usually be diagnosed by demonstrating markedly increased plasma concentrations of the cholesterol precursor, 7-dehydrocholesterol. We describe a simple and rapid